Start with a cash quote for an exact product
Tell the service you need the full self-pay amount for the proposed prescription. Ask it to identify the product, formulation and supply period before comparing totals. An approved branded pathway and a compounded pathway are separate decisions to discuss with the clinician. Compounded drugs are not FDA-approved, and price alone cannot establish suitability.
Three different budget problems
Ivim publishes a $75 monthly membership with medication extra: the missing medication line must be filled. CoreAge’s $79 versus $99 advertising conflict means even its advertised starting figure needs resolution. bmiMD’s $1,428 annual package raises a different question—how much you owe upfront and what happens to unused portions if care changes.
Keep introductory savings out of the steady budget
Mochi’s homepage promotion is not enough to establish an ongoing medication-and-care total. Build the ordinary renewal budget first. Then record any verified first-payment discount as a one-time difference. If the regular cost is unaffordable, a temporary reduction does not solve the ongoing payment problem.
Ask what a declined prescription costs
An evaluation does not guarantee medication. Before paying, request the terms if the clinician does not prescribe, recommends a different product or needs additional testing. Also ask about shipping and required follow-up charges. This turns an open-ended enrollment decision into a defined financial commitment without assuming that every charge will be refundable.
Sources & comparison notes
By Peptide Routes, using public provider information. Promotional conditions and personal treatment totals remain subject to confirmation. We have not enrolled as patients or tested clinical care.
- CoreAge Rx official treatment information
- CoreAge program overview
- CoreAge Rx terms of use
- CoreAge Rx refund and subscription policy
- bmiMD official offering
- Ivim Health official treatment information
- FDA Foundayo approval
- Mochi Health official treatment information
- FDA concerns with unapproved GLP-1 drugs